Lipodystrophy means body fat has shifted from its usual pattern.
The tesamorelin trials studied adults with HIV and extra belly fat linked to this change.
Connect the word to your concern
As of September 28, 2026, tesamorelin’s US approval covers adults with HIV and lipodystrophy who have excess belly fat.
HIV is the name of a virus. If this context does not match your reason for searching, ask the doctor to say that clearly.
The label says tesamorelin is not for managing weight loss.
Put your concern into ordinary words
You can describe what has changed and what bothers you without trying to diagnose it. Ask: “What do you think explains this change?” Then ask how that answer connects to the treatment being discussed.
Read the source notes
Source-check dates: September 28, 2026.
- DailyMed: the tesamorelin (EGRIFTA WR) label
- PubMed: the earlier main trial, by Falutz and colleagues
Ask for confirmation of the current product, rules and costs before deciding on care.